The procedure involved an investigational endovascular device, the Gore Excluder Thoracoabdominal Branch Endoprosthesis, which was placed into the patient’s aorta. The device works by preventing a rupture and maintaining blood flow to organs.
The patient received three small incisions and was hospitalized for six days. Both incision size and hospital stay typically required after traditional open heart surgery were reduced.
Clinical trials are being conducted at OSU and other hospitals in the region. Gore & Associates, the device manufacturer, is awaiting approval from the FDA for the device to become the first one to be made commercially available.
More articles on cardiology:
American Heart Association updates CPR guidelines: 5 key changes
Yale launches study on digital health tech for cardiac patients
MRIs safe for patients with implanted heart devices, study finds
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
